Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author holds a long position in SDGR.

← Back to Free Index

SDGR

Analysis as of: 2026-01-20

Schrödinger, Inc.

Schrödinger sells physics-based molecular modeling and enterprise informatics software to pharma and materials customers, plus runs partnered and proprietary drug discovery programs.

ai biotech healthcare software

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • Third Party Analyst Consensus

Summary

Physics-plus-AI aims to become discovery workflow infrastructure

The bull case is a steady transition from modeling toolkits to an enterprise workflow hub with higher usage, add-on modules, and partner-validated credibility. The bear case is slow pharma rollout plus competitive bundling that caps growth and keeps dilution risk alive.

Analysis

Thesis

SDGR can compound by turning “physics+AI” into the trusted molecular decision layer inside pharma: LiveDesign as the workflow hub + higher-velocity hosted simulation + attachable products (predictive tox, agentic automation), while partnering clinical assets to cap burn and convert scientific credibility into durable enterprise distribution.

Last Economy Alignment

Strong fit to cognition-as-commodity (prediction replaces bench work), but weaker than compute-supremacy leaders because it relies on third-party cloud/GPUs.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

3.7x (from 5 most recent analyses)

Reasoning

The upside comes from SDGR shifting from point tools to workflow gravity: LiveDesign integrations (e.g., Lilly TuneLab) drive higher seat expansion, hosted usage grows, and new modules (predictive tox + automation) raise net retention. Partnering clinical assets can reduce cash-burn narratives and let investors underwrite a cleaner recurring platform with “optionality,” supporting a durable mid-single-digit revenue multiple at scale.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The binding constraint is proof and adoption speed: enterprise customers move slowly and therapeutics value is gated by clinical data and partnering terms/timing. A secondary constraint is trust/security/uptime for hosted workflows; a major incident could stall scaling. Competitive risk is less “better science” and more bundling into broader R&D suites and internal build-outs.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

Jan 12, 2026 update emphasized 2026 priorities: scaling platform adoption, completing predictive tox beta, and securing development partners.
New/expanded strategic integrations highlighted: Lilly TuneLab integration into LiveDesign; Manas AI ultra-large-scale platform access agreement.
Street sentiment remains mixed: target adjustments continue, but attention is on Feb 2026 earnings/guidance as the next belief-reset.

Thesis update

Positive incremental validation from new integration/scale partners, but the core thesis (workflow gravity + partnered therapeutics optionality) is unchanged.

Upgrade to Builder to also access: Future Considerations

Third Party Analyst Consensus

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case